Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension

doi:10.12998/wjcc.v9.i1.47

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6994)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

264

WORD

111

HTML

2846

Figures (1-3)

435

Tables (1-3)

292

Sum=3948

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

311

Download

562

Sum=873

Publishing Process of This Article

Item

Count

Browse

564

Download

1609

Sum=2173

Jan 6, 2021 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Cases. Jan 6, 2021; 9(1): 47-60
Published online Jan 6, 2021. doi: 10.12998/wjcc.v9.i1.47

Full Size Figure Download Figure

Figure 3 The cumulative probability of discharge in patients. A: The cumulative probability of discharge (all patients); B: The cumulative probability of discharge (moderate cases); C: The cumulative probability of discharge (severe cases).

Citation: Tian C, Li N, Bai Y, Xiao H, Li S, Ge QG, Shen N, Ma QB. Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension. World J Clin Cases 2021; 9(1): 47-60
URL: https://www.wjgnet.com/2307-8960/full/v9/i1/47.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i1.47